| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/17/2005 | US20050059643 Medicaments for inhalation comprising a steroid and a betamimetic |
| 03/17/2005 | US20050059625 Immunostimulatory nucleic acid molecules |
| 03/17/2005 | US20050059615 saturated complexes of steroids with cyclodextrins, used for enhancing mucous membrane bioavailability of sex hormones or antiinflammatory agents |
| 03/17/2005 | US20050059595 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
| 03/17/2005 | US20050059594 Administering macrophage derived factor; oncomodulin |
| 03/17/2005 | US20050059583 For treating dry eyes; conjunctivitis |
| 03/17/2005 | US20050058767 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| 03/17/2005 | US20050058731 Treatment for cuticles or skin tissue; may also comprise avocado oil, primrose oil, juniper oil, grapefruit oil, chamomile oil, lavender oil with an effective amount of triclosan antifungal/antimicrobial agent |
| 03/17/2005 | US20050058714 String loaded with plurality of dosages of the microparticle; storage container for holding string; biasing structure for urging string toward open end; actuator selectively engageable |
| 03/17/2005 | US20050058713 Photosensitizer functionalised nanoparticles |
| 03/17/2005 | US20050058712 Aqueous dispersions of at least one biodegradable polymer |
| 03/17/2005 | US20050058711 Impermeable pouch having opposing walls defining a reservoir space therebetween; second wall includes plurality of openings defining diffusion area; coiled wire configured for fluid flow; thin envelope applied to patient's skin; transdermal drug delivery |
| 03/17/2005 | US20050058710 Porous matrix cont aining water insoluble drug; enhance dissolving in aqueous solution |
| 03/17/2005 | US20050058709 Methods for inhibiting photoaging of human skin using orally-administered agent |
| 03/17/2005 | US20050058708 Antibiotic product, use and formulation thereof |
| 03/17/2005 | US20050058707 Time-release dosage form delivered as dry or erodible solid at uniform rate contains polyoxyethylene glycol and/or polyvinylpyrrolidone carrier and disintegrant; free of surfactant |
| 03/17/2005 | US20050058706 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
| 03/17/2005 | US20050058705 Immediate release pharmaceutical granule compositions and a continuous process for making them |
| 03/17/2005 | US20050058704 Capsule containing active substance pellets |
| 03/17/2005 | US20050058703 Single molecular species genetically engineered gelatin and plasticizer |
| 03/17/2005 | US20050058702 Compositions capable of facilitating penetration across a biological barrier |
| 03/17/2005 | US20050058701 Active drug delivery in the gastrointestinal tract |
| 03/17/2005 | US20050058699 Mixture of nonsteroidal, antiinflammatory agent and a cyclooxygenase 2 (COX-2) inhibitor; sterilizing filtration membrane; administered topically or by injection to treat nervous system disorders or injuries |
| 03/17/2005 | US20050058698 The use of liposomes for treatment of inflammation and autoimmune disorders in mammals by reduction of Tumor necrosis factor |
| 03/17/2005 | US20050058696 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 03/17/2005 | US20050058695 Norethindrone sustained release formulations and methods associated therewith |
| 03/17/2005 | US20050058688 Device for the treatment and prevention of disease, and methods related thereto |
| 03/17/2005 | US20050058680 Process for the preparation of an emulsion |
| 03/17/2005 | US20050058679 Cosmetic preparation with 2-methyl-1,3-propanediol, or pentanediol or hexanediol with antioxidant and uv filter for skin moisturizer |
| 03/17/2005 | US20050058673 Decontamination of vegetables, meats or fruits by disinfection of such with antimicrobial solution containing lipid and enhancer such as bacteriocins, sugars and enzymes |
| 03/17/2005 | US20050058670 Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| 03/17/2005 | US20050058669 Skin care topical ointment |
| 03/17/2005 | US20050058667 Adjuvants for use in vaccines |
| 03/17/2005 | US20050058657 Vaccines for treatment of Aids |
| 03/17/2005 | US20050058609 Medicated toothpick |
| 03/17/2005 | US20050058607 Control of process humidity to produce large, porous particles |
| 03/17/2005 | US20050058606 Stable drug solution for aerosol administering; contining acid |
| 03/17/2005 | US20050058605 gas or air filled microballoons in aqueous suspension; imaging contrast agent; ultrasonic echography |
| 03/17/2005 | US20050058603 Biocompatible polymeric shell around hollow core; containing magnetic resonance imaging contrast agents |
| 03/17/2005 | US20050056170 Method and apparatus for emulsification |
| 03/17/2005 | DE69822327T2 Transdermales arzneistoff-abgabesystem für ein entzündungshemmendes analgetisches mittel enthaltend diclofenac diethylammonium salz, und verfahren zu dessen herstellung The transdermal drug-delivery system-containing medium for anti-inflammatory analgesic diclofenac diethylammonium salt, and process for its manufacture |
| 03/17/2005 | DE10338407A1 Neue Inhalationspulver enthaltend den CGRP-Antagonisten New inhalable powders containing the CGRP antagonist 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
| 03/17/2005 | DE10338403A1 Pulverformulierung, enthaltend den CGRP-Antagonisten Powder formulation comprising the CGRP-antagonists 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum Process for its preparation and its use as Inhalativum |
| 03/17/2005 | DE10338402A1 Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum Spray-dried, amorphous BIBN 4096, process for its preparation and its use as Inhalativum |
| 03/17/2005 | DE10338399A1 Mikropartikel, enthaltend den CGRP-Antagonisten Microparticles, comprising the CGRP-antagonists 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver Processes for their preparation and their use as Inhalaltionspulver |
| 03/17/2005 | DE10337186A1 Wässrige Wirkstoff-Lösung Aqueous drug solution |
| 03/17/2005 | DE10336841A1 Kosmetische Zusammensetzung zur Unterstützung des Sauerstofftransports in die Haut Cosmetic composition for enhancing oxygen delivery to the skin |
| 03/17/2005 | DE10012908B4 Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung Stabilized supersaturated matrix transdermal therapeutic systems and processes for their preparation |
| 03/17/2005 | CA2746516A1 Non-polar photosensitizer formulations for photodynamic therapy |
| 03/17/2005 | CA2538382A1 Antimicrobial compositions and methods |
| 03/17/2005 | CA2537802A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 03/17/2005 | CA2537776A1 Orally administrable dosage form for poorly soluble acidic and amphoteric active ingredients |
| 03/17/2005 | CA2537772A1 Method for the production of homogeneous liposomes and lipoplexes |
| 03/17/2005 | CA2537607A1 Granular sustained release preparation and production thereof |
| 03/17/2005 | CA2537488A1 Nicotine formulations and use thereof |
| 03/17/2005 | CA2537480A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof |
| 03/17/2005 | CA2537477A1 Capsules containing active substance pellets with different release profiles |
| 03/17/2005 | CA2537290A1 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| 03/17/2005 | CA2537246A1 Skin ulcer preventive or curative agent containing human recombinant hgf |
| 03/17/2005 | CA2536061A1 Polymeric systems for controlled drug therapy |
| 03/17/2005 | CA2535780A1 Antibiotic product, use and formulation thereof |
| 03/17/2005 | CA2535529A1 Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions |
| 03/17/2005 | CA2535060A1 Osmotic delivery of therapeutic compounds by solubility enhancement |
| 03/16/2005 | EP1514891A1 Aqueous dispersions of at least one biodegradable polymer |
| 03/16/2005 | EP1514884A1 Block copolymer comprising a vinyllactam block, cosmetic composition and use of this polymer in cosmetics |
| 03/16/2005 | EP1514877A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process |
| 03/16/2005 | EP1514560A1 Process for producing block copolymer/drug composite |
| 03/16/2005 | EP1514556A1 Botulinum toxin pharmaceutical compositions |
| 03/16/2005 | EP1514549A1 Powdery respiratory tonic composition |
| 03/16/2005 | EP1514548A2 Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension |
| 03/16/2005 | EP1514547A1 Controlled-release drug composition |
| 03/16/2005 | EP1514546A1 Medicament compositions based on tiotropium salts and on salmeterol salts |
| 03/16/2005 | EP1514539A2 Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
| 03/16/2005 | EP1514538A1 Sustained-release composition, process for producing the same and preparation thereof |
| 03/16/2005 | EP1514481A1 Use of neohesperidine dihydrochalcone in chewable tablets comprising vitamins and/or minerals |
| 03/16/2005 | EP1513889A1 Hydrous gel and production process and use of the hydrous gel |
| 03/16/2005 | EP1513853A2 Cardiolipin compositions, methods of preparation and use |
| 03/16/2005 | EP1513852A1 Phosphatidyl oligo glycerins and structural analogs |
| 03/16/2005 | EP1513587A1 Self-administered contraceptive injection of oily solution |
| 03/16/2005 | EP1513569A1 Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
| 03/16/2005 | EP1513565A1 Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
| 03/16/2005 | EP1513557A2 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases |
| 03/16/2005 | EP1513555A1 Formulations of quinapril and related ace inhibitors |
| 03/16/2005 | EP1513547A2 Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
| 03/16/2005 | EP1513546A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone |
| 03/16/2005 | EP1513540A1 Pharmaceutical compositions comprising abacavir and lamivudine |
| 03/16/2005 | EP1513535A2 Controlled release formulation of lamotrigine |
| 03/16/2005 | EP1513532A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 03/16/2005 | EP1513518A1 Use of nefopam for the treatment of nausea or emesis |
| 03/16/2005 | EP1513517A1 Formulation of nefopam and its use in the treatment of pain |
| 03/16/2005 | EP1513512A2 Soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors. |
| 03/16/2005 | EP1513511A1 (2s)-2-amino-4- [2-(ethanimidoylamino)ethyl]thio butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms |
| 03/16/2005 | EP1513509A2 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 03/16/2005 | EP1513508A1 Gastroretentive drug delivery system comprising an extruded hydratable polymer |
| 03/16/2005 | EP1513507A1 Transdermal analgesic systems with reduced abuse potential |
| 03/16/2005 | EP1513506A1 Targeting system comprising uniformly-sized nanoparticles with at least one polymer and at least one positively-charged polysaccharide and preparation method thereof |
| 03/16/2005 | EP1513505A1 An improved modified release preparation |
| 03/16/2005 | EP1513504A1 Sustained release oral dosage forms of gabapentin |
| 03/16/2005 | EP1513503A1 Extended release formulation of divalproex sodium |
| 03/16/2005 | EP1513502A1 Combination therapy for respiratory disorders |